These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33496861)

  • 61. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
    Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Front Immunol; 2019; 10():1666. PubMed ID: 31379857
    [No Abstract]   [Full Text] [Related]  

  • 62. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
    Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
    Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion.
    Garcia J; Hendel-Chavez H; De-Goer MG; L'Honneur AS; Dubessy AL; Taoufik Y; Stankoff B
    Mult Scler; 2021 Apr; 27(4):640-644. PubMed ID: 32686582
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population.
    Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C
    Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age.
    Briner M; Bagnoud M; Miclea A; Friedli C; Diem L; Chan A; Hoepner R; Salmen A
    Ther Adv Neurol Disord; 2019; 12():1756286419843450. PubMed ID: 31105768
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis].
    de Sá J; Ferreira J; Macedo AM
    Rev Neurol; 2023 Jan; 76(s01):S1-S6. PubMed ID: 36683265
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Chen C; Parks B; Miller C
    Ther Adv Neurol Disord; 2020; 13():1756286420915005. PubMed ID: 32426039
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
    J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Varicella-Zoster Reactivation in a Non-immunized Elderly Multiple Sclerosis Patient While on Delayed-Release Dimethyl Fumarate With Grade 2 Lymphopenia and Profoundly Low CD4+ and CD8+ Cell Counts: A Case Report.
    Daripa B; Lucchese S
    Cureus; 2022 Feb; 14(2):e22679. PubMed ID: 35386173
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report.
    Ciurleo R; Sessa E; Marino S; D'Aleo G; Bramanti P; Rifici C
    Medicine (Baltimore); 2019 Apr; 98(17):e15185. PubMed ID: 31027063
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
    Longbrake EE; Naismith RT; Parks BJ; Wu GF; Cross AH
    Mult Scler J Exp Transl Clin; 2015; 1():. PubMed ID: 26550483
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Dimethyl Fumarate in Multiple Sclerosis].
    Tanaka M; Shimizu Y
    Brain Nerve; 2017 Sep; 69(9):1041-1046. PubMed ID: 28900067
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.